Literature DB >> 21296553

Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature.

Jill A Hollway1, Michael G Aman.   

Abstract

Sleep disturbance is a common problem in children with developmental disabilities. Effective pharmacologic interventions are needed to ameliorate sleep problems that persist when behavior therapy alone is insufficient. The aim of the present study was to provide an overview of the quantity and quality of pharmacologic research targeting sleep in children with developmental disabilities. Efficacy studies of medications most likely to be prescribed to children are reviewed in detail. Medline and PsychInfo searches were performed to identify relevant clinical trials and case reports, published between 1975 and 2009. Key search terms included sleep, children, antihistamines, alpha adrenergic agonists, antidepressants, antipsychotics, melatonin, ramelteon, benzodiazepines, and nonbenzodiazepines. The literature search identified 58 articles that met the inclusion criteria. Well-controlled studies employing both objective polysomnography and subjective sleep measures are needed to determine the efficacy and safety of currently prescribed pediatric sleep medicines. Melatonin appears to be the most widely assessed agent and safest choice for children with developmental disabilities. Trazodone, mirtazapine, and ramelteon hold promise but require further study.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296553     DOI: 10.1016/j.ridd.2010.12.035

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  9 in total

1.  Correlates and risk markers for sleep disturbance in participants of the Autism Treatment Network.

Authors:  Jill A Hollway; Michael G Aman; Eric Butter
Journal:  J Autism Dev Disord       Date:  2013-12

Review 2.  Primary care for adults on the autism spectrum.

Authors:  Christina Nicolaidis; Clarissa Calliope Kripke; Dora Raymaker
Journal:  Med Clin North Am       Date:  2014-09       Impact factor: 5.456

Review 3.  Sleep disturbances in adolescents with ADHD: A systematic review and framework for future research.

Authors:  Jessica R Lunsford-Avery; Andrew D Krystal; Scott H Kollins
Journal:  Clin Psychol Rev       Date:  2016-10-23

4.  The trajectories of sleep disturbances in Rett syndrome.

Authors:  Kingsley Wong; Helen Leonard; Peter Jacoby; Carolyn Ellaway; Jenny Downs
Journal:  J Sleep Res       Date:  2014-09-14       Impact factor: 3.981

5.  Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder.

Authors:  Athanasios Maras; Carmen M Schroder; Beth A Malow; Robert L Findling; John Breddy; Tali Nir; Shiri Shahmoon; Nava Zisapel; Paul Gringras
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-10-11       Impact factor: 2.576

Review 6.  Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: A Literature Review.

Authors:  Sachin Relia; Vijayabharathi Ekambaram
Journal:  Med Sci (Basel)       Date:  2018-10-25

Review 7.  Characterizing the Interplay Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative Review.

Authors:  Charlotte Tye; Abigail K Runicles; Andrew J O Whitehouse; Gail A Alvares
Journal:  Front Psychiatry       Date:  2019-01-23       Impact factor: 4.157

Review 8.  Efficacy and safety of supplemental melatonin for delayed sleep-wake phase disorder in children: an overview.

Authors:  David Mantle; Marcel Smits; Myrthe Boss; Irene Miedema; Inge van Geijlswijk
Journal:  Sleep Med X       Date:  2020-08-19

Review 9.  Autism spectrum disorder in adults: diagnosis, management, and health services development.

Authors:  Clodagh M Murphy; C Ellie Wilson; Dene M Robertson; Christine Ecker; Eileen M Daly; Neil Hammond; Anastasios Galanopoulos; Iulia Dud; Declan G Murphy; Grainne M McAlonan
Journal:  Neuropsychiatr Dis Treat       Date:  2016-07-07       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.